SG11202010177UA - Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms - Google Patents
Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoformsInfo
- Publication number
- SG11202010177UA SG11202010177UA SG11202010177UA SG11202010177UA SG11202010177UA SG 11202010177U A SG11202010177U A SG 11202010177UA SG 11202010177U A SG11202010177U A SG 11202010177UA SG 11202010177U A SG11202010177U A SG 11202010177UA SG 11202010177U A SG11202010177U A SG 11202010177UA
- Authority
- SG
- Singapore
- Prior art keywords
- myosin
- isoforms
- pharmaceutically effective
- effective compounds
- compounds inhibiting
- Prior art date
Links
- 102100038303 Myosin-2 Human genes 0.000 title 1
- 101710204037 Myosin-2 Proteins 0.000 title 1
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1800129A HU231285B1 (en) | 2018-04-18 | 2018-04-18 | Compounds for selectively inhibiting myosin ii isoforms |
| PCT/HU2019/050017 WO2019202346A2 (en) | 2018-04-18 | 2019-04-18 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010177UA true SG11202010177UA (en) | 2020-11-27 |
Family
ID=89992670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010177UA SG11202010177UA (en) | 2018-04-18 | 2019-04-18 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11746112B2 (en) |
| EP (2) | EP3781263B1 (en) |
| JP (2) | JP7463344B2 (en) |
| KR (1) | KR20210010465A (en) |
| CN (2) | CN117924285A (en) |
| AU (1) | AU2019256801A1 (en) |
| BR (1) | BR112020021347A2 (en) |
| CA (1) | CA3097479A1 (en) |
| DK (1) | DK3781263T3 (en) |
| ES (1) | ES2963548T3 (en) |
| FI (1) | FI3781263T3 (en) |
| HU (2) | HU231285B1 (en) |
| IL (1) | IL278105B2 (en) |
| MA (1) | MA52298A (en) |
| MX (1) | MX2020011020A (en) |
| PH (1) | PH12020551734A1 (en) |
| PL (1) | PL3781263T3 (en) |
| PT (1) | PT3781263T (en) |
| SG (1) | SG11202010177UA (en) |
| SI (1) | SI3781263T1 (en) |
| WO (1) | WO2019202346A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231285B1 (en) | 2018-04-18 | 2022-08-28 | Printnet Kereskedelmi És Szolgáltató Kft. | Compounds for selectively inhibiting myosin ii isoforms |
| KR102559394B1 (en) | 2018-06-14 | 2023-07-27 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Nonmuscular myosin II inhibitors used for relapse substance use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ216519A (en) | 1985-06-13 | 1989-02-24 | Schering Corp | Polycyclic compounds and pharmaceutical compositions |
| JP2011510933A (en) * | 2008-01-31 | 2011-04-07 | モナシュ ユニバーシティ | Methods for treating thromboembolic disorders |
| WO2010120785A2 (en) | 2009-04-13 | 2010-10-21 | The Regents Of The University Of California | Methods and compositions for stem cell cultures |
| AU2011250651B2 (en) | 2010-05-05 | 2015-10-08 | Genea Ip Holdings Pty Limited | Media and methods for cell culture |
| EP2492687A1 (en) | 2011-02-23 | 2012-08-29 | Institut Gustave Roussy -Igr- | MYH10 as a new diagnostic marker of pathologies resulting from RUNX1 inactivation |
| US9492441B2 (en) | 2011-05-18 | 2016-11-15 | Michael E. DiSanto | Drug treatment of overactive bladder |
| US9994564B2 (en) * | 2011-05-18 | 2018-06-12 | Michael E. DiSanto | Myosin II ATPase inhibitor compounds |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| EP2777703B1 (en) * | 2013-03-15 | 2016-09-14 | Lonza Cologne GmbH | Compositions and methods for enhancing the therapeutic potential of stem cells |
| CA2937460A1 (en) * | 2014-02-18 | 2015-08-27 | Etablissement Francais Du Sang | High-resolution hla typing |
| AU2016243750B2 (en) | 2015-04-03 | 2022-02-03 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| WO2016180918A1 (en) | 2015-05-12 | 2016-11-17 | Platod | Combination of pharmacological and microfluidic features for improved platelets production |
| US10858357B2 (en) | 2016-01-29 | 2020-12-08 | Paris Sciences Et Lettres-Quartier Latin | Water-soluble myosin 2 inhibitors for the treatment of neurological, neuropathic or psychiatric diseases |
| WO2019164852A1 (en) | 2018-02-20 | 2019-08-29 | Edgewise Therapeutics, Inc. | Methods and compositions for treating movement disorders |
| HU231285B1 (en) | 2018-04-18 | 2022-08-28 | Printnet Kereskedelmi És Szolgáltató Kft. | Compounds for selectively inhibiting myosin ii isoforms |
| KR102559394B1 (en) | 2018-06-14 | 2023-07-27 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Nonmuscular myosin II inhibitors used for relapse substance use |
| WO2020097266A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
-
2018
- 2018-04-18 HU HU1800129A patent/HU231285B1/en unknown
-
2019
- 2019-04-18 MX MX2020011020A patent/MX2020011020A/en unknown
- 2019-04-18 AU AU2019256801A patent/AU2019256801A1/en active Pending
- 2019-04-18 CA CA3097479A patent/CA3097479A1/en active Pending
- 2019-04-18 SI SI201930626T patent/SI3781263T1/en unknown
- 2019-04-18 EP EP19779087.6A patent/EP3781263B1/en active Active
- 2019-04-18 BR BR112020021347-0A patent/BR112020021347A2/en unknown
- 2019-04-18 EP EP23184543.9A patent/EP4276102A3/en active Pending
- 2019-04-18 KR KR1020207033132A patent/KR20210010465A/en not_active Application Discontinuation
- 2019-04-18 WO PCT/HU2019/050017 patent/WO2019202346A2/en unknown
- 2019-04-18 CN CN202311771677.0A patent/CN117924285A/en active Pending
- 2019-04-18 US US17/048,206 patent/US11746112B2/en active Active
- 2019-04-18 PT PT197790876T patent/PT3781263T/en unknown
- 2019-04-18 MA MA052298A patent/MA52298A/en unknown
- 2019-04-18 PL PL19779087.6T patent/PL3781263T3/en unknown
- 2019-04-18 IL IL278105A patent/IL278105B2/en unknown
- 2019-04-18 CN CN201980040782.2A patent/CN112334191A/en active Pending
- 2019-04-18 FI FIEP19779087.6T patent/FI3781263T3/en active
- 2019-04-18 HU HUE19779087A patent/HUE063424T2/en unknown
- 2019-04-18 SG SG11202010177UA patent/SG11202010177UA/en unknown
- 2019-04-18 ES ES19779087T patent/ES2963548T3/en active Active
- 2019-04-18 JP JP2021506072A patent/JP7463344B2/en active Active
- 2019-04-18 DK DK19779087.6T patent/DK3781263T3/en active
-
2020
- 2020-10-17 PH PH12020551734A patent/PH12020551734A1/en unknown
-
2023
- 2023-06-30 US US18/345,772 patent/US11845758B2/en active Active
-
2024
- 2024-03-27 JP JP2024050808A patent/JP2024075759A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202010177UA (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
| GB201900665D0 (en) | 06557607002 | |
| GB202013791D0 (en) | Tidysqueeze 9 | |
| GB201918773D0 (en) | TidySqueeze 8 | |
| GB201913527D0 (en) | Nodens 2 | |
| GB201910340D0 (en) | CAERvest 1 | |
| GB201910320D0 (en) | Aleck 1 | |
| IL282557A (en) | Composition for preventing or treating sjogren's syndrome | |
| GB201904443D0 (en) | Aerocar 1 | |
| GB202115358D0 (en) | 13099098001 | |
| GB201917632D0 (en) | Concept 229 | |
| GB201902721D0 (en) | The infinity project | |
| GB201915914D0 (en) | Concept 227 | |
| GB201914147D0 (en) | Concept 225 | |
| GB201912624D0 (en) | Concept 224 | |
| GB201910990D0 (en) | Concept 223 | |
| GB201908824D0 (en) | Concept 33 | |
| GB201908829D0 (en) | Concept 29 | |
| GB201908823D0 (en) | Concept 33 | |
| GB201908827D0 (en) | Concept 32 | |
| GB201908826D0 (en) | Concept 23 | |
| GB201907929D0 (en) | Concept 30 | |
| GB201906107D0 (en) | Concept 2104 | |
| GB201904668D0 (en) | Concept 83 | |
| GB201902934D0 (en) | Concept 258 |